<DOC>
	<DOCNO>NCT01747278</DOCNO>
	<brief_summary>Evaluation efficacy safety profile trimethoprim/sulfamethoxazole Pneumocystis carinii pneumonia ( PCP ) prophylaxis Patients With Connective Tissue Diseases ( CTD ) treat high-dose glucocorticoid immunosuppressive agent . Open-labeled , randomize , prospective single-center clinical trial . Observation period 12 week .</brief_summary>
	<brief_title>Study Trimethoprim/Sulfamethoxazole PCP Prophylaxis CTD Patients</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Connective Tissue Diseases</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<criteria>Age 1865 year inform consent SLE , Sjögren syndrome , Polymyositis Dermatomyositis , define consensus classification criterion concomitant high dose glucocorticoid , define &gt; 1mg/kg/d prednisone equivalent concomitant cyclophosphamide , cyclosporine mycophenolate mofetil Pregnant lactate WBC＜ 4×10^9/L，PLT＜100×10^9/L Serum ALT AST &gt; 2 time upper limit normal Serum creatinine &gt; 1.5 mg/dL Severe hepatic , hematological , gastrointestinal , pulmonary , cardiovascular , neurological , endocrine cerebral disease Active infection , include HIV , HCV , HBV , tuberculosis PCP concomitant antibiotic trimethoprim/sulfamethoxazole Patient malignancy Drug allergy , especially trimethoprim/sulfamethoxazole</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Pneumocystis carinii pneumonia</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>trimethoprim/sulfamethoxazole</keyword>
</DOC>